This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Prestige Consumer (PBH) Q3 Earnings Top, Gross Margin Expands
by Zacks Equity Research
Prestige Consumer's (PBH) third-quarter fiscal 2024 results reflect the power of a well-positioned and diversified portfolio.
Illumina (ILMN) Q4 Earnings Surpass Estimates, Margin Down
by Zacks Equity Research
Illumina (ILMN) Q4 revenues increase year over year, driven by NovaSeq X instrument and consumables sales.
Baxter's (BAX) Q4 Earnings Top, Sales Rise on Strong Demand
by Zacks Equity Research
Baxter (BAX) reports better-than-expected fourth-quarter earnings and sales. BAX's fourth-quarter and full-year results reflect solid demand for a range of its medically essential products.
Envista (NVST) Q4 Earnings Miss Estimates, Margins Down
by Zacks Equity Research
Strong performance in the Speciality Products & Technologies segment contributes to Envista's (NVST) Q4 revenues.
McKesson (MCK) Beats on Q3 Earnings, Raises FY24 EPS View
by Zacks Equity Research
McKesson's (MCK) third-quarter fiscal 2024 results benefit from growth in the United States. Divestment hurts the International segment.
STERIS (STE) Q3 Earnings Top Estimates, Fiscal '24 Sales View Up
by Zacks Equity Research
STERIS' (STE) fiscal 2024 third-quarter results demonstrate the remarkable performance of the Healthcare segment.
Phibro (PAHC) Q2 Earnings and Revenues Top, Margins Down
by Zacks Equity Research
Phibro's (PAHC) fiscal 2024 second-quarter results reflect the strong performance of the Animal Health segment.
Is JPMorgan Diversified Return U.S. Mid Cap Equity ETF (JPME) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JPME
QIAGEN (QGEN) Q4 Earnings Miss, Operating Margin Expands
by Zacks Equity Research
QIAGEN's (QGEN) fourth-quarter performance reflects impressive CER sales growth and solid profitability.
GE HealthCare (GEHC) Q4 Earnings Beat, Volume & Price Improve
by Zacks Equity Research
GE HealthCare's (GEHC) fourth-quarter results benefit from continued demand for imaging, patient care and pharmaceutical diagnostic solutions. Sales gain from improved pricing.
5 Broker-Loved Stocks to Watch Amid Current Market Swings
by Maharathi Basu
We believe that stocks like American Airlines (AAL), Delta Air Lines (DAL), Cleveland-Cliffs (CLF), Best Buy (BBY) and Cardinal Health (CAH) should be on an investor's watchlist.
Jobless Claims Increased More Than Expected
by Zacks Equity Research
Jobless Claims Increased More Than Expected
Cardinal Health (CAH) Buys Specialty Networks to Boost Workflow
by Zacks Equity Research
Cardinal Health (CAH) acquires Specialty Network to technologically strengthen its specialty therapeutic areas. The acquisition also supports the company's ongoing Navista Network.
Jobless Claims & Productivity Leap Higher; CAH, IP, HON Report
by Mark Vickery
Once the market closes, we'll await earnings reports from three of the Magnificent 7 stocks: Apple, Amazon and Meta.
Cardinal Health (CAH) Beats on Q2 Earnings, Ups '24 EPS View
by Zacks Equity Research
Cardinal Health's (CAH) second-quarter fiscal 2024 results benefit from the Pharmaceutical segment's solid performance.
Should Value Investors Buy Cardinal Health (CAH) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Compared to Estimates, Cardinal (CAH) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Cardinal (CAH) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Cardinal Health, Inc. (CAH) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks.com featured highlights include Axonics, Enerpac Tool Group, Cardinal Health and Acuity Brands
by Zacks Equity Research
Axonics, Enerpac Tool Group, Cardinal Health and Acuity Brands are part of the Zacks Screen of the Week article.
Cardinal Health and RH have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Cardinal Health and RH are part of the Zacks Bull and Bear of the Day article.
Cardinal Health (CAH) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of 16.67% and 1.10%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Align Technology (ALGN) Q4 Revenues Top, Margins Expand
by Zacks Equity Research
Align Technology (ALGN) surpasses revenue and earnings estimates in the fourth quarter of fiscal 2023.
Bull of the Day: Cardinal Health (CAH)
by Ethan Feller
Cardinal Health enjoys a top Zacks rank and impressive EPS growth forecasts at a fair price
Medical Device Stocks' Earnings on Feb 1: RVTY, CAH & More
by Debanjana Dey
Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how CAH, RVTY, CNMD, SRDX and BDX are placed ahead of their earnings releases.